SOLICITATION NOTICE
66 -- Solexa Genome Analysis System
- Notice Date
- 8/8/2007
- Notice Type
- Solicitation Notice
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70119-NG
- Response Due
- 8/17/2007
- Archive Date
- 9/1/2007
- Description
- The National Cancer Institute (NCI) plans to procure on a sole source basis for a Solexa Genome Analysis System (Solexa Genetic Analyzer plus Cluster Station (CS)) along with the following components: Genetic Analyzer plus CS System 110 Power cords; DNA Sample kit; Standard Cluster Generation kits and; 35 Cycle Solexa Sequencing Kit with Illumina, Inc., 9885 Towne Centre Drive, San Diego, California 92121. This acquisition will be processed under FAR Part 12 Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.106-(b)(1) and 13.501-(a)(1) to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 334516 and the business size standard is 500 employees. The salient characteristics apply to the Solexa Genome Analysis System, components, and Technology to generate up to 1.0 G of DNA sequence data at 98.5% accuracy with a minimum 25-base read and an average Phred score of > Q17: - Whole genome resequencing, candidate region sequencing, ultra-deep resequencing for somatic mutations, metagenomics, genome-wide protein binding domain analysis, transcriptome analysis, gene expression profiling, and small RNA identification and quantification. - Digital gene expression profiles for direct study of any transcript from any gene, in any species. - Fully automated cluster creation and sequencing processes. - Data density available; highly economical order of magnitude increase in data recovery. - Software supporting the data pipeline with signal intensity analysis, DNA base calling, and DNA sequence alignment functions. The software package must include Sequencing Analysis software for image processing and base-calling with alignment, filtering, and data visualization functions. Alignment software must be included for reference sequence comparison and analysis visualization. - Multiplex capabilities to support at least eight separate analysis channels on the flowcell to allow up to 8 separate samples in a single run. - Accurate sequence determination regardless of sequence context or the presence of homopolymers stretches. - Technology to control single base additions in order to prevent multiple DNA base additions in homopolymer regions. Genetic Analyzer Features must include: - Automatic internal error detection system supports user warning and minimizes reagent waste. - Safety door lock sensors on the chassis for user safety. - 8-way pump with a pull configuration system minimizes carry over of reagents. - 1 million pixel CCD camera for high resolution performance and high data density. - CE compliant system supported world-wide including Europe. - Flowcell stage with X and Y-axis directional movement. Cluster Station Features must include: - Spill containment bulkheads and capture basins to prevent spills. - Front mounted indicator lights on chasis. - Removable holder allows either 0.2 mL 8- tube strips or 0.3 mL 8-tube strips for versatile user purposes. - Independent 8 channels to prevent contamination across reagent lines. - Fluidic pump on the Cluster Station is capable of pumping individually from eight tubes to allow faster reagent delivery and shorter run time. - 50 uL to 3.6 mL volume range provides various automated and manual volume delivery. - Cluster Station uses a disposable manifold assembly to prevent cross sample contamination. Manual Control Features must include: - Open software recipe control for customized run designs by user - Windows based software control - Manual control of system tests - Manual control of leak test software settings - Manual control of focus lasers - Manual flush of flow cell with selected reagents JUSTIFICATION: 1. Statutory authority: Statute: 13.106-(b)(1) and 13.501(a)(1) (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). (2) For Sole source acquisition of commercial items in excess of the simplified acquisition threshold conducted pursuant to subpart 13.5, the requirements at 13.501(a) apply. The Solexa clonal single molecular array technology combined with their sequencing-by-synthesis (SBS) technique on the Solexa 1G Genome analyzer can identify perfectly 25 bp sequence tag from each DNA molecule in a library and therefore allow investigators to identify the specific sequence of up to 1 gigabases in a single run. There are no other manufacturers known to the NCI that have either not yet marketed or are not capable of producing this number of DNA sequencing reads in a single run (20 million sequences). Without this efficient identification of DNA regions, the NCI cannot complete the studies on the function of chromatin, the regulation of genome expression, or the analysis of mutations in cancer specimens. The Solexa Genome Analysis System is solely manufactured and distributed by Illumina, Inc. The Solexa CSMA (Clonal Single Molecule Array), cluster growth, and sequence detection are internationally patented processes. Solexa (now part of Illumina) holds these patents. To meet rapidly emerging needs of NCI investigators, the acquisition of the Solexa Genetic Analyzer Solexa is necessary for the continued successes of NCI research and studies. This instrument (manufactured by Illumina) can generate 20 million sequence reads and 1 gigabase of total sequence. The applications of this technology in cancer research are far-reaching, including exon characterization, genome location analysis of regulatory factors, and gene expression analysis by sequence tags. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 1:00 PM ET on August 17, 2007. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Malinda Holdcraft, Contract Specialist at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-70119-NG on all correspondence.
- Record
- SN01365677-W 20070810/070808220658 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |